本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议。“时间的朋友”高瓴，正式退出百济神州5%以上股东的行列。从2023年首次减持至今，高瓴在百济神州的持股由2022年的11.02%骤降至4.89%。作为百济神州最早的机构投资者，高瓴陪伴这家药企从初创到三地上市，累计注资超13亿美元，彼此的关系早已超越普通财务投资范畴。高瓴大幅减仓，不是简单的资本套利，而是折射出中国生物医药行业在全球化...
Source Link本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议。“时间的朋友”高瓴，正式退出百济神州5%以上股东的行列。从2023年首次减持至今，高瓴在百济神州的持股由2022年的11.02%骤降至4.89%。作为百济神州最早的机构投资者，高瓴陪伴这家药企从初创到三地上市，累计注资超13亿美元，彼此的关系早已超越普通财务投资范畴。高瓴大幅减仓，不是简单的资本套利，而是折射出中国生物医药行业在全球化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.